Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Kamada is a drug manufacturers-specialty & generic business based in the US. Kamada shares (KMDA) are listed on the NASDAQ and all prices are listed in US Dollars. Kamada employs 355 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $4.45 |
|---|---|
| 52-week range | $4.22 - $6.96 |
| 50-day moving average | $4.77 |
| 200-day moving average | $5.62 |
| Wall St. target price | $11.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.15 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.45 from 2022-07-01
| 1 week (2022-06-24) | -3.47% |
|---|---|
| 1 month (2022-06-03) | -4.30% |
| 3 months (2022-04-04) | -20.39% |
| 6 months (2022-01-04) | -31.75% |
| 1 year (2021-07-02) | -24.06% |
|---|---|
| 2 years (2020-07-02) | -49.60% |
| 3 years (2019-07-03) | 5.56 |
| 5 years (2017-07-03) | 5.95 |
Valuing Kamada stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Kamada's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Kamada's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 8.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Kamada's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Kamada's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $5.4 million.
The EBITDA is a measure of a Kamada's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $106.8 million |
|---|---|
| Gross profit TTM | $30.3 million |
| Return on assets TTM | -0.25% |
| Return on equity TTM | -3.79% |
| Profit margin | -6.31% |
| Book value | $3.83 |
| Market capitalisation | $202.1 million |
TTM: trailing 12 months
We're not expecting Kamada to pay a dividend over the next 12 months.
Over the last 12 months, Kamada's shares have ranged in value from as little as $4.22 up to $6.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kamada's is 0.2339. This would suggest that Kamada's shares are less volatile than average (for this exchange).
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.